Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 70/100

PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day

Key Takeaway: PROCEPT BioRobotics has announced updated dates for its fourth quarter 2025 earnings conference call and Investor Day due to travel disruptions from inclement weather. The earnings report will be released on February 25, 2026, followed by a conference call. The in-person Investor Day is rescheduled for February 26, 2026, at NASDAQ Headquarters in New York City.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company is advancing patient care with innovative solutions.
  • Upcoming earnings call and investor day demonstrate transparency.
  • Robotic systems are designed to improve treatment outcomes for BPH.

Full Press Release Details

SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather.
The Company will report financial results for the fourth quarter of 2025 after market close onWednesday, February 25, 2026. The Company’s management will host a corresponding conference call beginning at4:30 p.m. Eastern Time.
The Company also announced it has rescheduled the in-person investor day event toThursday, February 26, 2026, at the NASDAQ Headquartersin New York City beginning at8:00am Eastern Time.
A live webcast of both events, as well as an archived recording, will be available on the “Investors” section of the Company’s website athttps://ir.procept-biorobotics.com. Each webcast will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
Important Safety InformationAll surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com

Frequently Asked Questions

When will PROCEPT BioRobotics report its Q4 2025 earnings?

The earnings report will be released on February 25, 2026.

What caused the rescheduling of the earnings call?

The rescheduling was due to significant travel disruptions from inclement weather.

When is the Investor Day event scheduled?

The Investor Day is rescheduled for February 26, 2026.

Where will the Investor Day take place?

The Investor Day will be held at NASDAQ Headquarters in New York City.

Last updated: Feb 24, 2026